Full Text View
Tabular View
No Study Results Posted
Related Studies
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
This study is currently recruiting participants.
Verified March 2013 by Stanford University
Study NCT00896493   Information provided by Stanford University

First Received on May 7, 2009.   Last Updated on March 26, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Mycoses
Sezary Syndrome
Lymphoma, T-Cell, Cutaneous
Bone Marrow Transplant Failure
Lymphoma, Non-Hodgkin
Cutaneous T-cell Lymphoma
Additional conditions recognized in this trial
Lymphoma
Lymphoma, T-Cell
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
anti-thymocyte globulin
cyclosporine
Additional drug interventions recognized in this trial
Antilymphocyte Serum
Cyclosporins
More general drug interventions related to this trial
Anti-Infective Agents
Antifungal Agents
Antirheumatic Agents
Dermatologic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Stanford University


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services